Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 342


A STAT3-NFkB/DDIT3/CEBPβ axis modulates ALDH1A3 expression in chemoresistant cell subpopulations.

Canino C, Luo Y, Marcato P, Blandino G, Pass HI, Cioce M.

Oncotarget. 2015 Mar 30. [Epub ahead of print]


High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma.

Nasu M, Emi M, Pastorino S, Tanji M, Powers A, Luk H, Baumann F, Zhang YA, Gazdar A, Kanodia S, Tiirikainen M, Flores E, Gaudino G, Becich MJ, Pass HI, Yang H, Carbone M.

J Thorac Oncol. 2015 Apr;10(4):565-76. doi: 10.1097/JTO.0000000000000471.


Metabolomic markers of altered nucleotide metabolism in early stage adenocarcinoma.

Wikoff WR, Grapov D, Fahrmann JF, DeFelice B, Rom WN, Pass HI, Kim K, Nguyen U, Taylor SL, Gandara DR, Kelly K, Fiehn O, Miyamoto S.

Cancer Prev Res (Phila). 2015 May;8(5):410-8. doi: 10.1158/1940-6207.CAPR-14-0329. Epub 2015 Feb 5.


Validation of a multiprotein plasma classifier to identify benign lung nodules.

Vachani A, Pass HI, Rom WN, Midthun DE, Edell ES, Laviolette M, Li XJ, Fong PY, Hunsucker SW, Hayward C, Mazzone PJ, Madtes DK, Miller YE, Walker MG, Shi J, Kearney P, Fang KC, Massion PP.

J Thorac Oncol. 2015 Apr;10(4):629-37. doi: 10.1097/JTO.0000000000000447.


Seminars in Thoracic and Cardiovascular Surgery. Introduction.

Pass HI, Rosengart TK.

Semin Thorac Cardiovasc Surg. 2014 Autumn;26(3):173. doi: 10.1053/j.semtcvs.2014.11.001. Epub 2014 Nov 11. No abstract available.


Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.

Guo G, Chmielecki J, Goparaju C, Heguy A, Dolgalev I, Carbone M, Seepo S, Meyerson M, Pass HI.

Cancer Res. 2015 Jan 15;75(2):264-9. doi: 10.1158/0008-5472.CAN-14-1008. Epub 2014 Dec 8.


Evaluation of clonal origin of malignant mesothelioma.

Comertpay S, Pastorino S, Tanji M, Mezzapelle R, Strianese O, Napolitano A, Baumann F, Weigel T, Friedberg J, Sugarbaker P, Krausz T, Wang E, Powers A, Gaudino G, Kanodia S, Pass HI, Parsons BL, Yang H, Carbone M.

J Transl Med. 2014 Dec 4;12:301. doi: 10.1186/s12967-014-0301-3.


Surgical resection of non-small cell lung cancer with N2 disease.

Donington JS, Pass HI.

Thorac Surg Clin. 2014 Nov;24(4):449-56. doi: 10.1016/j.thorsurg.2014.07.010. Epub 2014 Sep 11.


Methylation profile landscape in mesothelioma: possible implications in early detection, disease progression, and therapeutic options.

Zhang X, Tang N, Rishi AK, Pass HI, Wali A.

Methods Mol Biol. 2015;1238:235-47. doi: 10.1007/978-1-4939-1804-1_12.


Treatment of recalcitrant subcutaneous emphysema using negative pressure wound therapy dressings.

Towe C, Solomon B, Donington JS, Pass HI.

BMJ Case Rep. 2014 Nov 9;2014. pii: bcr2014205577. doi: 10.1136/bcr-2014-205577.


Validation of a blood protein signature for non-small cell lung cancer.

Mehan MR, Williams SA, Siegfried JM, Bigbee WL, Weissfeld JL, Wilson DO, Pass HI, Rom WN, Muley T, Meister M, Franklin W, Miller YE, Brody EN, Ostroff RM.

Clin Proteomics. 2014 Aug 1;11(1):32. doi: 10.1186/1559-0275-11-32. eCollection 2014.


CREB-induced inflammation is important for malignant mesothelioma growth.

Westbom CM, Shukla A, MacPherson MB, Yasewicz EC, Miller JM, Beuschel SL, Steele C, Pass HI, Vacek PM, Shukla A.

Am J Pathol. 2014 Oct;184(10):2816-27. doi: 10.1016/j.ajpath.2014.06.008. Epub 2014 Aug 8.


Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee.

Pass HI, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, Asamura H, Waller D, Edwards J, Weder W, Hoffmann H, van Meerbeeck JP, Rusch VW; IASLC Staging Committee and Participating Institutions.

J Thorac Oncol. 2014 Jun;9(6):856-64. doi: 10.1097/JTO.0000000000000181.


Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation.

Cioce M, Canino C, Goparaju C, Yang H, Carbone M, Pass HI.

Cell Death Dis. 2014 Apr 10;5:e1167. doi: 10.1038/cddis.2014.136.


Disulfiram suppresses growth of the malignant pleural mesothelioma cells in part by inducing apoptosis.

Cheriyan VT, Wang Y, Muthu M, Jamal S, Chen D, Yang H, Polin LA, Tarca AL, Pass HI, Dou QP, Sharma S, Wali A, Rishi AK.

PLoS One. 2014 Apr 1;9(4):e93711. doi: 10.1371/journal.pone.0093711. eCollection 2014.


Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications.

Suraokar MB, Nunez MI, Diao L, Chow CW, Kim D, Behrens C, Lin H, Lee S, Raso G, Moran C, Rice D, Mehran R, Lee JJ, Pass HI, Wang J, Momin AA, James BP, Corvalan A, Coombes K, Tsao A, Wistuba II.

Ann Oncol. 2014 Jun;25(6):1184-92. doi: 10.1093/annonc/mdu127. Epub 2014 Mar 24.


CARP-1 functional mimetics are a novel class of small molecule inhibitors of malignant pleural mesothelioma cells.

Jamal S, Cheriyan VT, Muthu M, Munie S, Levi E, Ashour AE, Pass HI, Wali A, Singh M, Rishi AK.

PLoS One. 2014 Mar 5;9(3):e89146. doi: 10.1371/journal.pone.0089146. eCollection 2014.


Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma.

Cioce M, Ganci F, Canu V, Sacconi A, Mori F, Canino C, Korita E, Casini B, Alessandrini G, Cambria A, Carosi MA, Blandino R, Panebianco V, Facciolo F, Visca P, Volinia S, Muti P, Strano S, Croce CM, Pass HI, Blandino G.

Oncogene. 2014 Nov 13;33(46):5319-31. doi: 10.1038/onc.2013.476. Epub 2013 Nov 18.


Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-α signaling.

Qi F, Okimoto G, Jube S, Napolitano A, Pass HI, Laczko R, Demay RM, Khan G, Tiirikainen M, Rinaudo C, Croce A, Yang H, Gaudino G, Carbone M.

Am J Pathol. 2013 Nov;183(5):1654-66. doi: 10.1016/j.ajpath.2013.07.029.


Biomarkers and prognostic factors for mesothelioma.

Pass HI.

Ann Cardiothorac Surg. 2012 Nov;1(4):449-56. doi: 10.3978/j.issn.2225-319X.2012.10.04. No abstract available.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk